HIV-1 p24 antibody

Catalog No. ABIN7849766

The Mouse Monoclonal anti-HIV-1 p24 antibody (Clone E12) (ABIN7849766) specifically detects HIV-1 p24 in ELISA. The antibody is reactive with Human samples.

Quick Overview for HIV-1 p24 antibody (ABIN7849766)

Target: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HIV-1 p24 antibody is un-conjugated

Application: ELISA

Clone: E12

Product Details anti-HIV-1 p24 Antibody

Purpose: Monoclonal Anti- HIV-1 p24 (Detection Ab)

Characteristics: This antibody may be used as in antibody pair experiments such as ELISA.

Purification: Protein A or G purified

Purity: >95 % by HPLC & SDS-PAGE

Immunogen: Recombinant human HIV-1 p24 Protein (Expression system with E.Coli).

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 0.9 % NaCl without preservative.

Preservative: Without preservative

Handling Advice: Avoid repeated freeze and thaw cycles.

Storage: -20 °C

Storage Comment: Aliquot and store at -20°C for long term (at least for one year). Avoid repeated freeze and thaw cycles.

Expiry Date: 12 months

Target Details for HIV-1 p24

Target: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Alternative Name: HIV-1 p24

Target Type: Viral Protein

Background: Acquired immune deficiency syndrome (HIV/AIDS) has been a major global health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in intracellular plasma membrane-connected structures termed virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. The transmembrane domain of Vpu and two motifs of the Vpu cytoplasmic domain are required for these functions. These motifs were notably involved in the control of the volume of VCCs by Vpu but were dispensable for the prevention of the specific accumulation of BST2 in these structures.